IGCS 2021: GynOnc
Expert Insight on Practice Changing From IGCS 2021 Informing Treatment for Endometrial, Ovarian, and Cervical Cancer

Released: September 21, 2021

Expiration: September 20, 2022

Alexandra Leary
Alexandra Leary, MD, PhD
Domenica Lorusso
Domenica Lorusso, MD, PhD

Activity

Progress
1
Course Completed

In this episode, Domenica Lorusso, MD, PhD, and Alexandra Leary, MD, PhD, provide expert insights on practice changing data from IGCS 2021 presented for endometrial, ovarian, and cervical cancers regarding:

  • A subgroup analysis from phase III KEYNOTE-775 evaluating lenvatinib plus pembrolizumab efficacy in patients with advanced endometrial cancer and dMMR status
  • A subgroup analysis from the phase I GARNET trial─cohorts A1 and A2─in patients with advanced endometrial cancer who had received either 1 or ≥2 prior lines of therapy
  • Data from the TOTEM trial reporting survival outcomes for patients undergoing intensive vs minimalist follow-up in following treatment for endometrial cancer
  • An exploratory analysis from the phase III ARIEL3 trial evaluating characteristics of patients with ovarian cancer with exceptional benefit from rucaparib
  • A post hoc analysis from the phase III NORA trial assessing efficacy of starting PARP inhibitor maintenance following either ≤4 vs >4 cycles of platinum-based chemotherapy
  • Highly anticipated results from the phase III EMPOWER-CERVICAL 1 trial of cemiplimab vs investigator’s choice chemotherapy in women with cervical cancer